arrow
B

Barbara Seitz-Polski

cote d'azur university
H指数:29
被引数:3,793

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to: “Letter to Editor “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs”: Important concerns on the validity of this article” [Food Chem. Toxicol. (2023), 178, 113897. https://doi.org/10.1016/j.fct.2023.113897]

勘误:关于“致编辑的信‘SARS-CoV-2 mRNA疫苗接种对先天免疫的抑制作用:G-四链体、外泌体和微小RNA的作用’”一文的重大有效性问题 [Food Chem. Toxicol. (2023), 178, 113897. https://doi.org/10.1016/j.fct.2023.113897]

2026-09-250
PRE
Anti-drug antibodies are common in membranous nephropathy and affect response to rituximab: a multicenter study

抗药抗体在膜性肾病中很常见,并影响利妥昔单抗的治疗反应:一项多中心研究

2025-10-010
OAAI
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy

抗利妥昔单抗抗体在原发性膜性肾病患者的发生及临床结局

2025-05-060
OA
Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy

人工智能指导磷脂酶A2受体相关膜性肾病患者的利妥昔单抗治疗

2025-04-160
OA
Antibodies and Membranous Nephropathy Recurrence After Kidney Transplantation
2024-12-010
OAAI
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies

Obinutuzumab和Ofatumumab在抗利妥昔单抗抗体的膜性肾病患者的治疗中比利妥昔单抗更有效

2024-12-010
OAAI
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis A Large Multicenter Cohort Study
2023-01-0122
OAAI